PharmaCorp Rx (TSXV:PCRX) 3-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PCRX PharmaCorp Rx Inc TSXV:PCRX
38 GF Score
Price C$0.48
! 2 Warning Signs
View Full Analysis

What is PharmaCorp Rx 3-Year EBITDA Growth Rate?

PharmaCorp Rx TSXV:PCRX +3.26% 38 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 525 Healthcare Providers & Services companies, PharmaCorp Rx ranks worse than 190476% on this metric.

PharmaCorp Rx's EBITDA per Share for the three months ended in Jun. 2026 was C$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

PharmaCorp Rx  (TSXV:PCRX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

PharmaCorp Rx 3-Year EBITDA Growth Rate Related Terms

PharmaCorp Rx 3-Year EBITDA Growth Rate Competitor Comparison

For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCorp Rx 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where PharmaCorp Rx's 3-Year EBITDA Growth Rate falls into.


TSXV:PCRX
38GF Score
PharmaCorp Rx Inc TSXV:PCRX
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCorp Rx 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
PharmaCorp Rx (TSXV:PCRX) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #999999 out of 525 companies in the Healthcare Providers & Services industry.
Is PharmaCorp Rx's 3-Year EBITDA Growth Rate too high?
PharmaCorp Rx's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, PharmaCorp Rx ranks #999999 out of 525 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmaCorp Rx has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's 3-Year EBITDA Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #999999 out of 525 companies for 3-Year EBITDA Growth Rate. This places PharmaCorp Rx in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PharmaCorp Rx and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. PharmaCorp Rx's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCorp Rx Business Description

Address 303 Wellman Lane, Suite 203, Saskatoon, SK, CAN, S7T 0J1
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
38GF Score

Get the complete analysis for TSXV:PCRX

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.48
Price